MatTek and NEXT Oncology Announce Licensing Agreement

The Boston-based biotech company will use an inventory of patient-derived cancer cells to develop new lab-grown tumor models to accelerate and refine oncology research, and provide more targeted treatments for cancer patients.

[For immediate release: Ashland, MA and San Antonio, TX, April 17, 2023] – MatTek Life Sciences and NEXT Oncology jointly announced today a licensing agreement that will have MatTek turn NEXT Oncology’s patient tumor cells into laboratory-grown in vitro tumor models for cancer research. With locations in Texas, Virginia, and Spain, NEXT Oncology is a global network of Phase I cancer research clinics dedicated to providing patients access to the latest treatments for advanced cancers. MatTek Life Sciences, a Boston-based biotech company, is a leader in the production of lab-grown human tissues and organs used worldwide as human-relevant replacements for animal testing.

Read the full article at